# Amgen Inc. – Consensus ‘buy’ rating and 1.2% Upside Potential

- Link: https://www.directorstalkinterviews.com/amgen-inc.consensus-buy-rating-and-1.2-upside-potential/4121131800
- Published: 2023-11-01T13:56:34+00:00
- Author: Charlotte Edwards

**Amgen Inc.** with ticker code (AMGN) now have 22 analysts in total covering the
stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges
between $301.79 and $174.47 calculating the average target price we see $258.80.
Now with the previous closing price of $255.70 this indicates there is a potential
upside of 1.2%. There is a 50 day moving average of $266.43 while the 200 day moving
average is $244.53. The total market capitalization for the company now stands at
137.21B. The stock price is currently at: $256.51 USD

 The potential market cap would be $138,872,261,405 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 17.3, revenue per share of $50.16
and a 7.88% return on assets.

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures
and delivers various human therapeutics. It operates in human therapeutics segment.
The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab),
Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha(
evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb),
Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO(
blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (
adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene
laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras,
Nplate, XGeva, and others. The Company focuses on human therapeutics for the treatment
of serious illness in the areas of inflammation, oncology/hematology, bone health,
cardiovascular disease, nephrology and neuroscience.

Share on: